secwatch.observer — SEC 8-K summary
======================================

Issuer:     Metagenomi Therapeutics, Inc. (MGX)
CIK:        0001785279
Form:       8-K
Filed at:   2026-11-10T21:07:15+00:00
Accession:  0001193125-26-455436
Event type: regulatory
Sentiment:  positive
Materiality: 0.78
Item codes: 2.02, 9.01
LLM model:  deepseek-v4.1-flash:cloud@v2

Metagenomi wins FDA IND clearance for MGX-001 in hemophilia A; Q3 cash $101.7M runway into 2028
--------------------------------------------------------------------------------

- FDA cleared the IND for MGX-001; the INTEGR8 Phase 1/2 trial in adults with moderately severe to severe hemophilia A is planned to start in 1H 2027.
- Initial safety, tolerability and Factor VIII activity data are expected in 2H 2027; additional preclinical data will be presented at ASH on Dec. 14, 2026 (Abstract 952).
- Cash, cash equivalents and available-for-sale marketable securities were $101.7 million as of Sept. 30, 2026, with runway expected into 2028.
- Q3 R&D expense was $17.5 million vs. $25.3 million a year earlier; G&A was $6.9 million, including a $1.2 million one-time net litigation settlement, vs. $6.2 million.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1785279/000119312526455436/0001193125-26-455436-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1785279/000119312526455436/mgx-20261110.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-455436

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer